Top

BMC Pulmonary Medicine

Published in:

Open Access 01-12-2024 | Idiopathic Pulmonary Fibrosis | Research

A prognostic model of idiopathic pulmonary fibrosis constructed based on macrophage and mitochondria-related genes

Authors: Yu Bao, Shiyuan Yang, Hailan Zhao, Yezhen Wang, Ke Li, Xue Liu, Wei Zhang, Xue Zhu

Published in: BMC Pulmonary Medicine | Issue 1/2024

Abstract

Background

Studies have shown that mitochondrial function and macrophages may play a role in the development of idiopathic pulmonary fibrosis (IPF). However, the understanding of the interactions and specific mechanisms between mitochondrial function and macrophages in pulmonary fibrosis is still very limited.

Methods

To construct a prognostic model for IPF based on Macrophage- related genes (MaRGs) and Mitochondria-related genes (MitoRGs), differential analysis was performed to achieve differentially expressed genes (DEGs) between IPF and Control groups in the GSE28042 dataset. Then, MitoRGs, MaRGs and DEGs were overlapped to screen out the signature genes. The univariate Cox analysis and the least absolute shrinkage and selection operator (LASSO) algorithm were implemented to achieve key genes. Furthermore, the independent prognostic analysis was employed. The ingenuity pathway analysis (IPA) was employed to further understand the molecular mechanisms of key genes.Next, the immune infiltration analysis was implemented to identify differential immune cells between two risk subgroups.

Results

There were 4791 DEGs between IPF and Control groups. Furthermore, 26 signature genes were achieved by the intersection processing. Three key genes including ALDH2, MCL1, and BCL2A1 were achieved, and the risk model based on the key genes was created. In addition, a nomogram for survival forecasting of IPF patients was created based on riskScore, Age, and Gender, and we found that key genes were associated with classical pathways including ‘Apoptosis Signaling’, ‘PI3K/AKT Signaling’, and so on. Next, two differential immune cells including Monocytes and CD8 T cells were identified between two risk subgroups. Moreover, we found that MIR29B2CHG and hsa-mir-1-3p could regulate the expression of ALDH2.

Conclusion

We achieved 3 key genes including ALDH2, MCL1,, and BCL2A1 associated with IPF, providing a new theoretical basis for clinical treatment of IPF.

Available only for authorised users

Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol. 2022;17:515–46. https://doi.org/10.1146/annurev-pathol-042320-030240.CrossRefPubMed

Kirby T. Living with idiopathic pulmonary fibrosis. Lancet Respir Med. 2021;9(2):136–8. https://doi.org/10.1016/s2213-2600(20)30562-2.CrossRefPubMed

Podolanczuk AJ, Thomson CC, Remy-Jardin M, Richeldi L, Martinez FJ, Kolb M, et al. Idiopathic pulmonary fibrosis: state of the art for 2023. Eur Respir J. 2023;61(4). https://doi.org/10.1183/13993003.00957-2022.

Zhao X, Kwan JYY, Yip K, Liu PP, Liu FF. Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020;19(1):57–75. https://doi.org/10.1038/s41573-019-0040-5.CrossRefPubMed

Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karampitsakos T, et al. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. Pharmacol Ther. 2021;222:107798. https://doi.org/10.1016/j.pharmthera.2020.107798.CrossRefPubMed

Luppi F, Kalluri M, Faverio P, Kreuter M, Ferrara G. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir Res. 2021;22(1):109. https://doi.org/10.1186/s12931-021-01711-1.CrossRefPubMedPubMedCentral

Ghumman M, Dhamecha D, Gonsalves A, Fortier L, Sorkhdini P, Zhou Y, et al. Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment. Eur J Pharm Biopharm. 2021;164:1–12. https://doi.org/10.1016/j.ejpb.2021.03.017.CrossRefPubMedPubMedCentral

Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021;21(1):411. https://doi.org/10.1186/s12890-021-01783-1.CrossRefPubMedPubMedCentral

Alfaro TM, Robalo Cordeiro C. Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us? Ther Adv Respir Dis. 2020;14:1753466620910092. https://doi.org/10.1177/1753466620910092.CrossRefPubMedPubMedCentral

10.

Stainer A, Faverio P, Busnelli S, Catalano M, Della Zoppa M, Marruchella A, et al. Molecular biomarkers in idiopathic pulmonary fibrosis: state of the art and future directions. Int J Mol Sci. 2021;22(12). https://doi.org/10.3390/ijms22126255.

11.

Liu Y, Birsoy K. Metabolic sensing and control in mitochondria. Mol Cell. 2023;83(6):877–89. https://doi.org/10.1016/j.molcel.2023.02.016.CrossRefPubMedPubMedCentral

12.

Monzel AS, Enríquez JA, Picard M. Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction. Nat Metab. 2023;5(4):546–62. https://doi.org/10.1038/s42255-023-00783-1.CrossRefPubMed

13.

Aghali A, Koloko Ngassie ML, Pabelick CM, Prakash YS. Cellular Senescence in Aging lungs and diseases. Cells. 2022;11(11). https://doi.org/10.3390/cells11111781.

14.

Larson-Casey JL, Deshane JS, Ryan AJ, Thannickal VJ, Carter AB. Macrophage Akt1 kinase-mediated Mitophagy modulates apoptosis resistance and pulmonary fibrosis. Immunity. 2016;44(3):582–96. https://doi.org/10.1016/j.immuni.2016.01.001.CrossRefPubMedPubMedCentral

15.

Yao C, Guan X, Carraro G, Parimon T, Liu X, Huang G, et al. Senescence of alveolar type 2 cells Drives Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021;203(6):707–17. https://doi.org/10.1164/rccm.202004-1274OC.CrossRefPubMedPubMedCentral

16.

Schafer MJ, White TA, Iijima K, Haak AJ, Ligresti G, Atkinson EJ, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017;8:14532. https://doi.org/10.1038/ncomms14532.CrossRefPubMedPubMedCentral

17.

Sakamoto K, Furukawa T, Yamano Y, Kataoka K, Teramachi R, Walia A, et al. Serum mitochondrial DNA predicts the risk of acute exacerbation and progression of idiopathic pulmonary fibrosis. Eur Respir J. 2021;57(1). https://doi.org/10.1183/13993003.01346-2020.

18.

Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020;877:173090. https://doi.org/10.1016/j.ejphar.2020.173090.CrossRefPubMed

19.

Wang L, Zhang Y, Zhang N, Xia J, Zhan Q, Wang C. Potential role of M2 macrophage polarization in ventilator-induced lung fibrosis. Int Immunopharmacol. 2019;75:105795. https://doi.org/10.1016/j.intimp.2019.105795.CrossRefPubMed

20.

Rao LZ, Wang Y, Zhang L, Wu G, Zhang L, Wang FX, et al. IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages. Cell Death Differ. 2021;28(4):1270–83. https://doi.org/10.1038/s41418-020-00650-6.CrossRefPubMed

21.

Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med. 2011;184(5):569–81. https://doi.org/10.1164/rccm.201010-1719OC.CrossRefPubMed

22.

Li S, Zhang H, Chang J, Li D, Cao P. Iron overload and mitochondrial dysfunction orchestrate pulmonary fibrosis. Eur J Pharmacol. 2021;912:174613. https://doi.org/10.1016/j.ejphar.2021.174613.CrossRefPubMed

23.

Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013;5(205):205ra136. https://doi.org/10.1126/scitranslmed.3005964.CrossRefPubMedPubMedCentral

24.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https://doi.org/10.1093/nar/gkv007.CrossRefPubMedPubMedCentral

25.

Ito K, Murphy D. Application of ggplot2 to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol. 2013;2(10):e79. https://doi.org/10.1038/psp.2013.56.CrossRefPubMedPubMedCentral

26.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innov (Cambridge (Mass)). 2021;2(3):100141. https://doi.org/10.1016/j.xinn.2021.100141.CrossRef

27.

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor infiltrating Immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–59. https://doi.org/10.1007/978-1-4939-7493-1_12.CrossRefPubMedPubMedCentral

28.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504. https://doi.org/10.1101/gr.1239303.CrossRefPubMedPubMedCentral

29.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262.CrossRefPubMed

30.

Long P, He M, Yan W, Chen W, Wei D, Wang S, et al. ALDH2 protects naturally aged mouse retina via inhibiting oxidative stress-related apoptosis and enhancing unfolded protein response in endoplasmic reticulum. Aging. 2020;13(2):2750–67. https://doi.org/10.18632/aging.202325.CrossRefPubMedPubMedCentral

31.

Tsai HY, Hsu YJ, Lu CY, Tsai MC, Hung WC, Chen PC, et al. Pharmacological activation of Aldehyde dehydrogenase 2 protects against Heatstroke-Induced Acute Lung Injury by modulating oxidative stress and endothelial dysfunction. Front Immunol. 2021;12:740562. https://doi.org/10.3389/fimmu.2021.740562.CrossRefPubMedPubMedCentral

32.

Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol. 2014;20(47):17756–72. https://doi.org/10.3748/wjg.v20.i47.17756.CrossRefPubMedPubMedCentral

33.

Jonczyk R, Ronconi S, Rychlik M, Genschel U. Pantothenate synthetase is essential but not limiting for pantothenate biosynthesis in Arabidopsis. Plant Mol Biol. 2008;66(1–2):1–14. https://doi.org/10.1007/s11103-007-9248-6.CrossRefPubMed

34.

Tan Q, Link PA, Meridew JA, Pham TX, Caporarello N, Ligresti G, et al. Spontaneous lung fibrosis resolution reveals Novel Antifibrotic regulators. Am J Respir Cell Mol Biol. 2021;64(4):453–64. https://doi.org/10.1165/rcmb.2020-0396OC.CrossRefPubMedPubMedCentral

35.

Xia G, Xu J, Chen M, Jin J, Wang X, Ye Y. Loss of ALDH2 aggravates mitochondrial biogenesis disorder in cardiac myocytes induced by TAC. Biochem Biophys Res Commun. 2023;639:189–96. https://doi.org/10.1016/j.bbrc.2022.12.001.CrossRefPubMed

36.

Kang P, Wang J, Fang D, Fang T, Yu Y, Zhang W, et al. Activation of ALDH2 attenuates high glucose induced rat cardiomyocyte fibrosis and necroptosis. Free Radic Biol Med. 2020;146:198–210. https://doi.org/10.1016/j.freeradbiomed.2019.10.416.CrossRefPubMed

37.

Xu T, Guo J, Wei M, Wang J, Yang K, Pan C, et al. Aldehyde dehydrogenase 2 protects against acute kidney injury by regulating autophagy via the Beclin-1 pathway. JCI Insight. 2021;6(15). https://doi.org/10.1172/jci.insight.138183.

38.

Lin L, Tao JP, Li M, Peng J, Zhou C, Ouyang J, et al. Mechanism of ALDH2 improves the neuronal damage caused by hypoxia/reoxygenation. Eur Rev Med Pharmacol Sci. 2022;26(8):2712–20. https://doi.org/10.26355/eurrev_202204_28601.CrossRefPubMed

39.

Brobyn RD. Nabumetone in the treatment of active adult rheumatoid arthritis. Am J Med. 1987;83(4b):50–4. https://doi.org/10.1016/0002-9343(87)90594-8.CrossRefPubMed

40.

Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14(1):67. https://doi.org/10.1186/s13045-021-01079-1.CrossRefPubMedPubMedCentral

41.

Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 2012;19(1):67–74. https://doi.org/10.1038/cdd.2011.158.CrossRefPubMed

42.

Liang R, Yung MMH, He F, Jiao P, Chan KKL, Ngan HYS, et al. The stress-inducible BCL2A1 is required for ovarian Cancer metastatic progression in the Peritoneal Microenvironment. Cancers (Basel). 2021;13(18). https://doi.org/10.3390/cancers13184577.

43.

Kroner A, Greenhalgh AD, Zarruk JG, Passos Dos Santos R, Gaestel M, David S. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. Neuron. 2014;83(5):1098–116. https://doi.org/10.1016/j.neuron.2014.07.027.CrossRefPubMed

44.

Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, et al. Monocyte Count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2021;204(1):74–81. https://doi.org/10.1164/rccm.202003-0669OC.CrossRefPubMedPubMedCentral

45.

Brodeur TY, Robidoux TE, Weinstein JS, Craft J, Swain SL, Marshak-Rothstein A. IL-21 promotes pulmonary fibrosis through the induction of profibrotic CD8 + T cells. J Immunol. 2015;195(11):5251–60. https://doi.org/10.4049/jimmunol.1500777.CrossRefPubMed

46.

Shiba S, Nakamoto N, Chu PS, Ojiro K, Taniki N, Yamaguchi A, et al. Acetaldehyde exposure underlies functional defects in monocytes induced by excessive alcohol consumption. Sci Rep. 2021;11(1):13690. https://doi.org/10.1038/s41598-021-93086-y.CrossRefPubMedPubMedCentral

47.

Or CR, Huang CW, Chang CC, Lai YC, Chen YJ, Chang CC. Obatoclax, a Pan-BCL-2 inhibitor, Downregulates Survivin to induce apoptosis in human colorectal carcinoma cells Via suppressing WNT/β-catenin signaling. Int J Mol Sci. 2020;21(5). https://doi.org/10.3390/ijms21051773.

48.

Gupta R, Kadhim MM, Turki Jalil A, Qasim Alasheqi M, Alsaikhan F, Khalimovna Mukhamedova N, et al. The interactions of docetaxel with tumor microenvironment. Int Immunopharmacol. 2023;119:110214. https://doi.org/10.1016/j.intimp.2023.110214.CrossRefPubMed

49.

Morelon E, Mamzer-Bruneel MF, Peraldi MN, Kreis H. Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transpl. 2001;16(1):18–20. https://doi.org/10.1093/ndt/16.1.18.CrossRef

50.

Hybiak J, Broniarek I, Kiryczyński G, Los LD, Rosik J, Machaj F, et al. Aspirin and its pleiotropic application. Eur J Pharmacol. 2020;866:172762. https://doi.org/10.1016/j.ejphar.2019.172762.CrossRefPubMed

51.

Sad K, Parashar P, Tripathi P, Hungyo H, Sistla R, Soni R, et al. Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. Free Radic Biol Med. 2021;177:299–312. https://doi.org/10.1016/j.freeradbiomed.2021.11.001.CrossRefPubMed

52.

Lei Y, Tang L, Chen Q, Wu L, He W, Tu D, et al. Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism. Nat Commun. 2022;13(1):6862. https://doi.org/10.1038/s41467-022-34671-1.CrossRefPubMedPubMedCentral

53.

Shi Y, Fu Y, Zhang X, Zhao G, Yao Y, Guo Y, et al. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunol Immunother. 2021;70(1):61–73. https://doi.org/10.1007/s00262-020-02653-1.CrossRefPubMed

54.

Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821–7. https://doi.org/10.1124/dmd.32.8.821.CrossRefPubMed

55.

Fan G, Liu J, Wu Z, Li C, Zhang Y. Development and validation of the prognostic model based on autophagy-associated genes in idiopathic pulmonary fibrosis. Front Immunol. 2022;13:1049361. https://doi.org/10.3389/fimmu.2022.1049361. Published 2022 Dec 12.CrossRefPubMedPubMedCentral

56.

Li Y, Deng Y, He J. A novel prognostic index based on the analysis of glycolysis-related genes in idiopathic pulmonary fibrosis. Med (Baltim). 2023;102(11):e33330. https://doi.org/10.1097/MD.0000000000033330.CrossRef

Title: A prognostic model of idiopathic pulmonary fibrosis constructed based on macrophage and mitochondria-related genes
Authors: Yu Bao
Shiyuan Yang
Hailan Zhao
Yezhen Wang
Ke Li
Xue Liu
Wei Zhang
Xue Zhu
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Idiopathic Pulmonary Fibrosis
Published in: BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-024-02976-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Association between computed tomography-quantified respiratory muscles and chronic obstructive pulmonary disease: a retrospective study

Changes in lung mechanics and ventilation-perfusion match: comparison of pulmonary air- and thromboembolism in rats

Aerobic exercise training engages the canonical wnt pathway to improve pulmonary function and inflammation in COPD

A case of hypercalcemia from Pneumocystis jirovecii in an immunosuppressed non-HIV patient

Longitudinal assessment of interstitial lung abnormalities on CT in patients with COPD using artificial intelligence-based segmentation: a prospective observational study

Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials